Compare Align Technology, Inc. (ALGN) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Align Technology, Inc. vs GeneDx Holdings Corp — how do they compare? Align Technology, Inc. trades at $182.04 (market cap $12.86B), while GeneDx Holdings Corp trades at $65.11 (market cap $1.95B). The key difference: Align Technology, Inc. is far larger — about 6.6× GeneDx Holdings Corp's market cap, and Align Technology, Inc. is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| ALGN | WGS | |
|---|---|---|
Market Cap | $12.86B | $1.95B |
Sector | Health | Technology |
52-Week High | $207.19 | $167.51 |
52-Week Low | $124.88 | $34.51 |
Enterprise Value | $11.92B | $1.95B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Align Technology (ALGN) trades at $179.45, up 0.72% with a bullish technical outlook from moving averages. The company maintains solid profitability with a 10.5% net margin and has beaten EPS estimates for three consecutive quarters. Recent developments include a new manufacturing facility in India and upcoming Q2 2026 earnings on July 29, 2026.
ALGN offers growth potential with a consensus price target of $218.40, representing 22% upside, supported by 73% analyst buy ratings. Risks include European regulatory scrutiny and North American demand pressures. The stock's valuation at 30x P/E requires sustained earnings growth to justify further gains.
GeneDx Holdings (WGS) trades at $65.64, down 5.4% over 24 hours, with a bullish technical signal from moving averages. The company reported revenue of $427.54 million in 2025 but a net loss of $21.02 million, with profitability metrics like ROE at -30.42% indicating financial strain. Recent news highlights a securities class action lawsuit filed against the company, alleging misleading statements related to the Fabric Genomics acquisition.
While analyst consensus remains strongly bullish with a $75.40 price target, the stock faces significant risks from ongoing litigation and persistent losses. Investment appeal hinges on the company's ability to improve margins and navigate legal challenges, but current fundamentals suggest caution despite optimistic Wall Street ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Align Technology, Inc.
Align is the leading manufacturer of clear dental aligners globally, having pioneered the technology with the introduction of its Invisalign branded aligners in 1998. Since then, Invisalign has become a household name, having treated over 10 million patients with malocclusion (misaligned teeth) through orthodontist and dentist-guided treatment plans. The company maintains dominant market share of clear aligners, despite the introduction of direct-to-consumer competitors upon the expiration of key patents that began in 2017. Align also manufactures intraoral scanners (iTero), used for orthodontic treatment and restorative dental procedures (digital models for crowns, veneers, and implants).
Read more on ALGN →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
